Idera Pharmaceuticals Inc (NASDAQ:IDRA) recently presented its new pre- clinical data that demonstrates the ability of the TLR or Toll-like receptor antagonist, IMO-8400, for inhibiting survival and the proliferation of the B-cell lymphoma cells that harbor the oncogenic MYD88- L265P genetic mutation. The data adds to the increasing body of research that supports IDRA’s efforts to develop its IMO-8400 for treating the genetically-defined forms of its B-cell lymphoma. Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares after opening at $2.92 moved to $3.09 on last trade day and at the end of the day closed at $2.77. Company price to sales ratio in past twelve months was calculated as 4853.39 and price to cash ratio as 7.76. Idera Pharmaceuticals Inc (NASDAQ:IDRA) showed a negative weekly performance of -23.27%.
Wal-Mart is delving deeper into financial services at its stores and shaking up the money transfer business. The world’s largest retailer introduced a new money transfer service Thursday that it says will cut fees for its low-income customers by up to 50 per cent compared with similar services elsewhere. Shares of MoneyGram International Inc (NASDAQ:MGI) and Western Union plunged almost immediately Thursday after the announcement. Moneygram International Inc (NASDAQ:MGI) shares fell -17.68% in last trading session and ended the day on $14.81. Moneygram International Inc (NASDAQ:MGI) return on equity ratio is recorded as -12.80% and its return on assets is 1.10%. Moneygram International Inc (NASDAQ:MGI) yearly performance is -8.01%.
Shares in Net 1 UEPS Technologies Inc (NASDAQ:UEPS) plunged on Thursday as investors reacting to a Constitutional Court ruling dumped the volatile stock. The ruling that the R10 billion social grant tender, previously awarded to Net 1 UEPS Technologies Inc (NASDAQ:UEPS), had to be re-run was the culmination of a nearly two-year legal battle and the beginning of certainty since the disputed contract was allocated to the company in January 2012. Net 1 UEPS Technologies Inc (NASDAQ:UEPS) shares moved down -5.52% in last trading session and was closed at $8.98, while trading in range of $7.03 – $9.18. Net 1 UEPS Technologies Inc (NASDAQ:UEPS) year to date (YTD) performance is 2.92%.
Yesterday, Zalicus Inc. (NASDAQ:ZLCS) revealed it had confirmed a deal with Epirus Biopharmaceuticals for a merger of the latter with a Zalicus Inc (NASDAQ:ZLCS) subsidiary in an all-stock transaction. The merger will result in Zalicus Inc (NASDAQ:ZLCS) being renamed and working under the management of Epirus Biopharmaceuticals. The leadership of the newly formed entity will be led by the current President and CEO of Epirus, Amit Munshi. Zalicus Inc (NASDAQ:ZLCS) on last trading day company shares ended up $1.21. Zalicus Inc (NASDAQ:ZLCS) distance from 50-day simple moving average (SMA50) is -11.16%. Analysts mean target price for the company is $1.20.
Leave a Reply